Anti-Apolipoprotein C-I (GOAT) Antibody
APOLIPOPROTEIN C-I Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Host | Goat |
---|---|
Conjugate | Unconjugated |
Target Species | Human |
Reactivity | Human |
Clonality | Polyclonal |
Application ![]()
| WB, IHC, E, IP, I, LCI |
Application Note | Anti-Apolipoprotein antibodies have been used for indirect trapping ELISA for quantitation of antigen in serum using a standard curve, for immunoprecipitation and for western blotting for highly sensitive qualitative analysis. |
Physical State | Liquid (sterile filtered) |
Buffer | 0.125 M Sodium Borate, 0.075 M Sodium Chloride, 0.005 M EDTA, pH 8.0 |
Immunogen | apoLipoprotein Type C-I produced synthetically in full-length form (not selected epitopes) using conventional peptide technology. |
Preservative | 0.01% (w/v) Sodium Azide |
Gene ID | 341 |
---|---|
Other Names | 341 |
Purity | This product has been prepared by immunoaffinity chromatography using immobilized antigens followed by extensive cross-adsorption against other apoLipoproteins and human serum proteins to remove any unwanted specificities. Typically less than 1% cross reactivity against other types of apoLipoprotein was detected by ELISA against purified standards. This antibody reacts with human apoLipoprotein C-I and has negligible cross-reactivity with Type A-I, A-II, B, C-II, C-III, E and J apoLipoproteins. Specific cross reaction of anti-apoLipoprotein antibodies with antigens from other species has not been determined. Non-specific cross reaction of anti-apoLipoprotein antibodies with other human serum proteins is negligible. |
Storage Condition | Store vial at 4° C prior to opening. This product is stable at 4° C as an undiluted liquid. Dilute only prior to immediate use. For extended storage, mix with an equal volume of glycerol, aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. |
Precautions Note | This product is for research use only and is not intended for therapeutic or diagnostic applications. |
Name | APOC1 |
---|---|
Function | Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein. |
Cellular Location | Secreted. |
Tissue Location | Synthesized mainly in liver and to a minor degree in intestine. Also found in the lung and spleen |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This antibody is suitable for cardiovascular research.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.